[Halcinonide-neomycin-nystatin in the treatment of dermatosis and cutaneous candidiasis].
Sixty-four patients were treated for inflammatory dermatoses or cutaneous candidiasis with a new corticosteroid combination drug, halcinonide-neomycin-nystatin (HNN). In 50 patients treated for psoriasis, atopic dermatitis, eczematous dermatitis, or neurodermatitis, HNN was evaluated in a double-blind, paired comparison study with hydrocortisone (HC) as the control drug. HNN was superior in 24 patients, HC was superior in 6, and the responses were equal in 18. The overall therapeutic response was Excellent with HNN in 29 patients as compared to 14 with HC. The anticandidal properties of HNN were assessed in a parallel study with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The most frequently treated conditions were "erosio interdigitalis blastomycotica" and candidal lesions of the neck region. The response with HNN was Excellent in 7 of 14 patients as compared to 4 out of 14 treated with I-HC.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002179:Candidiasis, Cutaneous / Q000188:drug therapy*; D003872:Dermatitis / Q000188:drug therapy*; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D008297:Male; D009355:Neomycin / Q000627:therapeutic use*; D009761:Nystatin / Q000627:therapeutic use*; D011282:Pregnenediones / Q000627:therapeutic use*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D011282:Pregnenediones; D009761:Nystatin; D014222:Triamcinolone Acetonide; D009355:Neomycin; D006854:Hydrocortisone
Halcinónido-neomicina-nistanina en el tratamiento de dermatósis y candidiásis cutánea